Dr. Ly Vu receives Journey Award celebrating Canada’s outstanding immigrant women in STEMM

Congratulations to Dr. Ly Vu for receiving a Journey Award from the Canada Centre for Immigrant Women in STEM. The Journey Awards recognize and honour the journeys of immigrant women in STEMM who exemplify leadership, innovation and community service.

Dr. Vu is a scientist at BC Cancer, professor at UBC, and a Canada Research Chair in RNA biology in hematological malignancies.

Natural Language Processing can reduce workload, increase timeliness and improve quality of breast cancer care

A new BC Cancer project has been shown to expedite the triaging of breast cancers and accelerate the initiation of treatment. 

The CAN-TRI-NLP, or a “CANcer TRIage system to expedite care with Natural Language Processing” project, was funded through the Ministry of Health's Innovation Pathway Program to explore a new expedited breast cancer triage system for faster initiation of appropriate treatment, chemotherapy or surgery.

Exercise improves survival for colon cancer patients

In a world-first clinical trial, a team of international researchers working with the Canadian Cancer Trials Group (CCTG) have demonstrated that a structured exercise program significantly improves survival for colon cancer patients by reducing the risk of disease recurrence and new primary cancers.

The groundbreaking seventeen-year study involved researchers from UBC’s Faculty of Medicine as well as researchers at 55 sites across Canada, Australia and the United Kingdom.

New Inpatient Clinical Trials Unit Launches in Vancouver to Advance Blood Cancer Treatment Across BC

British Columbia’s first dedicated inpatient clinical trials unit for early-phase therapies in blood cancers has been launched by Vancouver Coastal Health in collaboration with BC Cancer physicians and scientists. Located at Vancouver General Hospital (VGH), the new Hematology Research Unit will deliver revolutionary therapies — including first-in-human treatments such as advanced immunotherapies like CAR T-cell therapy — to patients with relapsed or treatment-resistant hematological diseases.

Back to top